<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3571">
  <stage>Registered</stage>
  <submitdate>27/05/2012</submitdate>
  <approvaldate>27/05/2012</approvaldate>
  <nctid>NCT01620749</nctid>
  <trial_identification>
    <studytitle>Of 18F MEL050 Using PET/CT in Metastatic Melanoma</studytitle>
    <scientifictitle>A Phase 0 Exploratory Microdosing Study of 6-18fluoro-N-[2-(Diethylamino)Ethyl]Pyridine-3-carboxamide (18F MEL050) Using PET/CT in Patients With Metastatic Melanoma</scientifictitle>
    <utrn />
    <trialacronym>MEL050</trialacronym>
    <secondaryid>10/11</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Metastatic Melanoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Malignant melanoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: other - 18F MEL050

Experimental: MEL050 - 


Treatment: other: 18F MEL050
Diagnostic intervention to establish the safety and biodistribution of MEL050 in participants with melanoma.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety of 18F MEL050 administration as measured by occurrence of adverse clinical, biochemical or haematological events following 18F MEL050 administration.</outcome>
      <timepoint>Up to 28 days following 18F MEL050 administration (+/- 7 days)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of injected 18F MEL050 dose in organs of interest.</outcome>
      <timepoint>10, 30, 60 and 120 minutes post 18F MEL050 administration</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of unmetabolized 18F MEL050 in plasma and urine after radiotracer administration.</outcome>
      <timepoint>60, 120 and 180 minutes post 18F MEL050 administration.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Absorbed organ doses and whole body dose expressed as milliSv/200MBq administered dose.</outcome>
      <timepoint>10, 30, 60 and 120 minutes post 18F MEL050 administration</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Written informed consent obtained prior to any protocol-specific procedures

          -  Male and female patients with histologically confirmed melanoma

          -  At least one site of metastatic disease, as demonstrated on the pre-study 18F FDG
             PET/CT scan performed as part of routine clinical care

          -  Age &gt;/= 18 years

          -  Life expectancy &gt;/=3 months

          -  ECOG performance score of 0-2</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Pregnant or breastfeeding females

          -  Systemic anti-melanoma therapy within the 2 weeks prior to the pre-study 18F FDG
             PET/CT scan until after the 18F MEL050 PET/CT scan

          -  Patients whose clinical care may be compromised because of the delay resulting from
             performance of the 18F MEL050 PET/CT scan

          -  Patients whose only metastatic lesion is in the Central Nervous System

          -  Patients with urinary incontinence or patients who cannot comfortably hold their urine
             for more than 90 minutes

          -  Any serious medical condition which the investigator feels may interfere with the
             procedures or evaluations of the study

          -  Patients unwilling or unable to comply with protocol and patients with a history of
             non compliance or inability to grant informed consent.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 0</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>12</actualsamplesize>
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2012</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Peter MacCallum Cancer Centre - East Melbourne</hospital>
    <postcode>3002 - East Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Cooperative Research Centre for Biomedical Imaging Development</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to investigate the safety and potential effectiveness of the
      imaging compound 18F MEL050 for finding sites of melanoma.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01620749</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Grant McArthur</name>
      <address>Peter MacCallum Cancer Centre, Australia</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>